 2. The patient has a diagnosis of either stage IIIB, stage IV, or advanced, incurable NSCLC, and failed at least one front-line metastatic NSCLC chemotherapy regimen. Patients who have failed adjuvant or locally advanced therapy within 6 months are also eligible to participate in study. 